Clinical trials: CMS
Healthy Volunteer
A Phase 1 Clinical Study in Healthy Volunteers to Investigate the Drug-drug Interaction Between Multiple Doses of RO7033877 and Multiple Doses of Colistin Methanesulfonate Sodium (CMS)
This single center, open-label, randomized study will investigate the drug-drug interaction potential between multiple doses of RO7033877 and multiple doses of colistin methanesulfonate sodium (CMS).
- Trial name
- NCT02156323
- Testing
- CMS, RO7033877, RO7033877 + CMS
- Where
- Netherlands
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Congenital Myasthenic Syndrome, CMS
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
The purpose of this study is to assess the safety and tolerability of ARGX-119 in adult participants with DOK7- Congenital Myasthenic Syndromes.
- Trial name
- NCT06436742
- Testing
- ARGX-119
- Where
- 9 sites in United States, Canada and 4 more
- Volunteers
- 15 people
- Sponsor
- argenx
Sepsis, Severe Sepsis
ED Tracking Sheet Implementation
The purpose of this study is to assess whether implementation of an ED Sepsis Tracking Sheet effects the percentage of goal-directed sepsis criteria met in a tertiary care academic Emergency Department.
- Conditions
- Sepsis, Severe Sepsis, Systemic Inflammatory Response Syndrome
- Trial name
- NCT05213923
- Testing
- ED Sepsis Tracking Sheet
- Where
- United States
- Volunteers
- 194 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Evaluate the Safety and Tolerability, Healthy and Overweight or Obese Participants
Phase 1 Study of Ascending Doses of CMS-D008 in Healthy and Overweight/Obese Adults
This study is a first-in-human clinical trial of CMS-D008 conducted in Chinese healthy and overweight or obese adult participants, consisting of three parts: Part-1 Single Ascending Dose (SAD) study (hereinafter referred to as…
- Trial name
- NCT07518589
- Testing
- CMS-D008
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.
Congenital Myasthenic Syndrome, CMS
A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)
The purpose of this study is to assess efficacy and safety of adimanebart in participants at least 12 years of age with DOK7-, MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS).
- Trial name
- CoMetS (NCT07746089)
- Testing
- Adimanebart IV
- Volunteers
- 105 people
- Sponsor
- argenx
Healthcare Fraud Schemes, Kickback Networks
Healthcare Integrity & Anti-Fraud Enforcement
The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities.
- Conditions
- Healthcare Fraud Schemes, Kickback Networks, Supply Chain Vulnerabilities, Governance Failures
- Trial name
- PHX-AFK-US (NCT07217730)
- Testing
- Validator-Governed Reform & Regulatory Escalation Protocol, Coalition-Grade Validator Dashboard Module (CVDM-1), Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Truway Health, Inc.
Pacemaker, Implantable Cardioverter Defibrillators
Study Evaluating the Use of MRI on CMS Patients
The overall objective of this protocol is to evaluate the safety and utility of diagnostic MRI in Center for Medicare and Medicaid Services (CMS) beneficiaries with pacemakers and Implantable Cardioverter Defibrillators (ICD) and…
- Trial name
- PM/ICD (NCT02513056)
- Testing
- MRI
- Where
- United States
- Volunteers
- 872 people
- Sponsor
- University of Pennsylvania
Heart Failure
Treating Heart Failure With hPSC-CMs
Heart failure has a high morbidity and mortality because the heart is one of the least regenerative organs in the human body. Drug treatments for heart failure manage symptoms but do not restore lost myocytes.
- Trial name
- HEAL-CHF (NCT03763136)
- Testing
- hPSC-CM Therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Leukemia
Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes
The goal of this clinical research study is to find the highest tolerable dose of OPB-31121 that can be given to patients with leukemia or myelodysplastic syndrome (MDS).
- Trial name
- NCT01029509
- Testing
- OPB 31121
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Congenital Myasthenic Syndrome
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4
Participants will attend up to 4 study visits to collect clinical assessments. The assessments will evaluate participants' symptoms and quality of life to understand disease activity in patients with CMS due to mutations in DOK7…
- Trial name
- NCT06078553
- Where
- 33 sites in United States, Austria and 10 more
- Volunteers
- 100 people
- Sponsor
- argenx
Colorectal Neoplasms
The Role of the Tumor Molecular Profile (CMS), UGT1A1 Genotype and Beta-glucuronidase Activity of the Intestinal Microbiota for Treatment Efficiency, Toxicity, Survival and Quality of Life in Patients With Metastatic or Unresectable Colorectal Cancer During Irinotecan-based Systemic Treatment
Irinotecan-based systemic therapy is a treatment option for metastatic or unresectable colorectal cancer. However, this therapy has two major disadvantages, namely, an unpredictable response to the treatment and severe side…
- Trial name
- OPTIMA (NCT05655780)
- Where
- Netherlands
- Volunteers
- 104 people
- Sponsor
- Maastricht University Medical Center
Heart Failure, Heart Failure At NYHA Stage III or IV
IPSC-CMs Combined with LVAD or CABG for the Treatment of Heart Failure
This clinical trial investigates the safety, feasibility, and therapeutic potential of a combined approach using HiCM-188 cardiomyocyte injection delivered intramyocardially alongside either LVAD implantation or CABG surgery in…
- Trial name
- NCT06866600
- Testing
- low dose CABG+iPSC-CMs, High dose CABG/LVAD+iPSC-CMs, CABG/LVAD+Saline
- Where
- China
- Volunteers
- 40 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome
Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
Primary: The primary objective of this study under the original protocol was to provide neuromuscular specialists and neurologists access to amifampridine phosphate therapy for their patients with LEMS, CMS or downbeat nystagmus…
- Conditions
- Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired
- Trial name
- EAP-001 (NCT02189720)
- Testing
- Amifampridine Phosphate
- Where
- United States
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Uterine Fibroids With Menorrhagia
Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia
Objective This study evaluates whether CMS-D002 capsules are effective in treating menorrhagia in participants with uterine fibroids associated with menorrhagia.
- Trial name
- NCT07402369
- Testing
- CMS-D002 Capsules 10 mg, CMS-D002 Capsules 25 mg, CMS-D002 Capsules 50 mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.
Paroxysmal Nocturnal Hemoglobinuria, PNH, Complement-mediated Kidney Disease
A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants
This study is a first-in-human (FIH) trial of CMS-D017 conducted in healthy Chinese adult participants, consisting of two parts: Part 1-a single ascending dose (SAD) study (referred to as Part 1 SAD), and Part 2-a multiple…
- Trial name
- NCT07462780
- Testing
- CMS-D017 Capsule
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.
Diabetes Mellitus, Type 2, Chronic Disease
Impact of CMS Reimbursement Policy Supporting Care Coordination in Louisiana
Investigators propose to use a natural experiment design to examine the impacts of the new CPT code (99490) for chronic care management on health outcomes.
- Trial name
- NCT03136471
- Where
- United States
- Volunteers
- 22,242 people, healthy volunteers welcome
- Sponsor
- Tulane University
Osteoarthritis, Degenerative Arthritis
Journey II BCS CMS Total Knee System Compared to Other PS Total Knee Systems in PT Setting
The primary objective of the study is to determine how the short-term outcome of subjects implanted with the JOURNEY™ II BCS Total Knee System compares to subjects implanted with other PS total knee systems, and to determine if…
- Conditions
- Osteoarthritis, Degenerative Arthritis, Traumatic Arthritis
- Trial name
- NCT02820766
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Smith & Nephew, Inc.
Heart Failure
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
The purpose of this clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting…
- Trial name
- HEAL-AHF (NCT06340048)
- Testing
- HiCM-188 therapy
- Where
- China
- Volunteers
- 36 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Multiple Myeloma
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT).
- Trial name
- NCT03127761
- Testing
- Allogeneic Hematopoietic Stem Cell Transplant
- Where
- United States
- Volunteers
- 544 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Healthy Volunteers
Study on the Mass Balance of [14C] CMS-D002 in Healthy Adult Participants in China
This phase 1, single-group study will evaluate the mass balance of [14C] CMS-D002 after a single oral dose in healthy adult participants in China.
- Trial name
- NCT07788482
- Testing
- [14C] CMS-D002
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.